
GT Biopharma Investor Relations Material
Latest events

Q1 2025
15 May, 2025

Q4 2024
21 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from GT Biopharma Inc
Access all reports
GT Biopharma Inc. is a biotechnology company focused on developing immuno-oncology therapies for cancer treatment. The company specializes in TriKE (Tri-specific Killer Engager) technology, which is designed to enhance the ability of natural killer (NK) cells to target and destroy cancer cells. GT Biopharma’s pipeline includes investigational treatments for hematologic malignancies and solid tumors. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.
Key slides for GT Biopharma Inc


Corporate Presentation
GT Biopharma Inc


Corporate Presentation
GT Biopharma Inc
Latest articles
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
Ticker symbol
GTBP
Country
🇺🇸 United States